GSK plc (LSE/NYSE ... is based on the promising results from the SWIFT and ANCHOR clinical trials. If approved, depemokimab would be the first ultra-long-acting biologic with a six-month dosing ...

Key drugs Blenrep and Depemokimab show significant potential, with impressive Phase 3 results, expected to boost GSK's revenues by an extra £7 billion. Despite some IRA and clinical trial risks ...

GSK plc announced that the European Medicines ... multi-centre phase III clinical trials. The trials assessed the efficacy and safety of depemokimab adjunctive therapy in 382 and 380 adult and ...

GSK plc announced that new drug applications ... multi-centre phase III clinical trials.1 The trials assessed the efficacy and safety of depemokimab adjunctive therapy in 382 and 380 adult and ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

LONDON - GSK plc (LSE/NYSE ... on the positive outcomes of the SWIFT and ANCHOR phase III clinical trials. In the SWIFT trials, depemokimab demonstrated a significant reduction in exacerbation ...

The presentation was sent to our distribution list by email, and you can also find it on gsk.com ... will differentiate based on clinical data. And the market research that we have in these ...

It covers the Severe Asthma pipeline drug profiles, including clinical and nonclinical ... Severe Asthma Pipeline Outlook GSK 3511294, also known as depemokimab, is a long acting, interleukin ...

Investing.com -- GSK (LON ... The company’s research and development efforts continue to shape its future outlook. Currently, 71 specialty medicines and vaccines are in clinical development ...

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks Consensus Estimate of 53 cents. Core earnings declined 20% year over ...

GSK's chief executive, Emma Walmsley, accentuated the group's pipeline in comments on the results, pointing to "11 positive phase 3 trials reported so far this year and [...planned] launches for ...